stockportfolio.pro
Stocks / HALO vs OSCR
HALO vs OSCR
Halozyme Therapeutics, Inc. and Oscar Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Halozyme Therapeutics, Inc. (HALO) | Oscar Health, Inc. (OSCR) | |
|---|---|---|
| Market cap | $8.4B | $8.5B |
| Revenue (latest FY) | $1.40B | $11.70B |
| Net income (latest FY) | $316.89M | $-443.15M |
| Revenue growth (5y CAGR) | 39.2% | 90.8% |
| Net margin | 22.7% | -3.8% |
| Return on equity | 649.2% | -45.3% |
| P/E ratio | 24.9 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 1 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HALO — free Open OSCR — freeFrequently asked questions
Which is bigger, HALO or OSCR?
Oscar Health, Inc. is larger by market capitalization — $8.5B versus $8.4B.
Which grows faster, HALO or OSCR?
Over the last five fiscal years, Oscar Health, Inc. grew revenue faster — 90.8%/yr versus 39.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.